2020 Archives

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

HIV.gov | December 29, 2020

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

ViiV Healthcare | December 21, 2020

Update to CDC's Treatment for Gonococcal Infections, 2020

CDC | December 18, 2020

Fact Sheet for Recipients and Caregivers: Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older

FDA | December 2020

Long-Lasting Anti-AIDS Meds Eliminate 'Psychic Toll' Of Daily Pill 

NPR | November 19, 2020

Salivary flow, amylase, and total protein in hospitalized patients with HIV infection / AIDS complications 

Afr Health Sci. 2020 Jun;20(2):597-604. doi: 10.4314/ahs.v20i2.7.

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Merck | November 16, 2020

Changes to SELZENTRY (maraviroc) labeling to include safety and PK data in pediatric patients weighing at least 2 kg

FDA | November 2, 2020

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV 

PipelineReview.com | October 17, 2020

Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV 

PipelineReview.com | October 16, 2020

Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment 

POZ | October 16, 2020

Gilead's Biktarvy sustains viral suppression and tolerability in Asian HIV patients 

BSA bureau | October 15, 2020

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel

Journal of the American Medical Association | October 14, 2020

Switching HIV Meds to Long-Acting Cabenuva May Not Require Oral Lead-In 

POZ | October 9, 2020

Dentists, do you know which drugs do not mix with remdesivir?

Dr Bicuspid | October 8, 2020

Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified

PipelineReview.com | October 8, 2020

HIV Regimen of Islatravir and Pifeltro Doesn’t Appear to Affect Kidney Function

POZ | October 7, 2020

Injectable HIV therapy should save money if adherence is better than to oral therapies 

aidsmap | October 7, 2020

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial 

PubMed | 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1

Gilead's Truvada faces Teva generics assault amid Descovy switching campaign 

FiercePharma | October 2, 2020

ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices

ViiV Healthcare | September 28, 2020

Pharmacists Play a Critical Role in Managing Changes to HIV Care During COVID-19 

Pharmacy Times | September 16, 2020

Integrase Inhibitors Tied to Fewer Potentially Harmful Drug Interactions

POZ | August 31, 2020

FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling

FDA | August 6, 2020

Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial 

Antimicrob Agents Chemother. 2020 Aug 3;AAC.00838-20. doi: 10.1128/AAC.00838-20

PREZCOBIX and EVOTAZ: Pediatric Label Updates

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

The Lancet | July 25, 2020

EPCLUSA: updates to labeling (liver transplant)

Long-acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study

NIH | July 7, 2020

Dolutegravir Use at Conception Not Tied to Neural Tube Defects After All

POZ | July 7, 2020

The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection

AIDS 2020: 23rd International AIDS Conference Virtual, July 6-10, 2020

HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men

IAC 2020 July 6-10 Virtual SF

New Findings on Gilead's Biktarvy Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults

Financialbuzz.com | July 4, 2020

Clinical targeting of HIV capsid protein with a long-acting small molecule

Nature. 2020 Jul 1. doi: 10.1038/s41586-020-2443-1

New Data Shows Promise Involving Lenacapavir for the Treatment of HIV 

BioSpace | July 2, 2020

Treatment Action Group’s 2020 HIV Pipeline Report 

TAG | July 2020

RUKOBIA: New Drug Approved for HIV-1

FDA | July 2020

FDA expands Gardasil 9 approval for head and neck cancer prevention

Healio | June 15, 2020

Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research

Expert Opin Drug Deliv. 2020 Jun 17. doi: 10.1080/17425247.2020.1783233

FDA expands Gardasil 9 approval for head and neck cancer prevention

Healio | June 15, 2020


FDA Approves Drug to Treat Infants and Children with HIV

FDA | June 12, 2020

Safety highlights from the DISCOVER Trial

Gilead | June 2020

Trivicay Now Available for Babies as Young as 4 Weeks

Infectious Disease Special Edition | June 12, 2020

National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2020 Annual Report

NASTAD | June 5, 2020

Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

NIH | May 22, 2020

New COVID-19 CDC Resources on PrEP and Liver Disease

HIV.gov | May 21, 2020

NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men, and Transgender Women

HIV.gov | May 18, 2020

HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe 

Infectious Disease Advisor | May 7, 2020

FDA authorizing the emergency use of remdesivir for treatment of COVID-19

Updated 2020 National AIDS Drug Assistance Program (ADAP) Formulary Database

NASTAD | April 2020

NIH-funded research leads to pediatric labeling updates for doxycycline, clindamycin and caffeine citrate

NIH | April 2, 2020

Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection

NCBI | March 2020

ADAP Advocacy Association Applauds Pharmaceutical Industry Efforts on Protecting the Drug Supply Chain during the Coronavirus Pandemic 

ADAP Advocacy Association | March 26, 2020

ViiV Healthcare on Friday announced that Health Canada has approved Cabenuva (cabotegravir and rilpivirine)

The Pharma Letter | March 21, 2020

EPCLUSA: Labeling Updates for Pediatric Patients

FDA | March 19, 2019

Newer anti-HIV drugs safest, most effective during pregnancy

NIH | March 11, 2020


CROI 2020 March 11

New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults

Gilead Sciences, Inc | March 9, 2020

ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

ViiV | March 9, 2020

Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV

CROI 2020, March 8-11, 2020, Boston

Initial Weight, Low CD4/CD8, Low Activity Drive Weight Gains After InSTI Switch

CROI 2020, March 8-11, 2020, Boston

F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks

CROI 2020, March 8-11, 2020, Boston

Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP

CROI 2020, March 8-11, 2020, Boston

Maraviroc Does Not Demonstrate Clinical Benefit in Advanced HIV 

Infectious Disease Advisor | March 5, 2020

SYMTUZA: Pediatric Labeling Updates

FDA | March 4, 2020

Monthly Injectable Antiretroviral Therapy — Version 1.0 of a New Treatment Approach

The New England Journal of Medicine | March 4, 2020

Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

Gilead Sciences, Inc | November 8, 2019

A Secure Drug Supply Chain is the Best Anti-Counterfeiting Technology We Have

ADAP Advocacy Association | February 27, 2020

Rockefeller grants commercial license for the development of new HIV drugs

Rockerfeller | February 26, 2020

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis

Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.

Adding maraviroc to standard treatment for advanced HIV does not improve outcomes 

Healio | February 10, 2020

Just one dose of HPV vaccine may confer durable cervical cancer protection

Healio | February 10, 2020

AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis

abbvie | January 31, 2020

VEMLIDY: Labeling Updates

FDA | February 4, 2020

Opioid Prescribing Behaviors — Prescription Behavior Surveillance System, 11 States, 2010–2016

CDC | January 31, 2020

A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)

NATAP | January 2020

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

ViiV Healthcare | London, 10 January 2020

Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 9, 2020

FDA Programs to Register HIV Drugs for Use in Resource-Constrained Settings 

Infectious Disease Advisor | January 3, 2020